

Educational material authorized by the Spanish Agency for Medicines and Medical Devices (AEMPS) June 2017

▲ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.  
Darzalex is a biological drug.

▲ **DARZALEX (DARATUMUMAB)**

## PATIENT ALERT CARD

# Daratumumab



Doctors  
phone

Doctors Name/  
Clinic, Center or  
Hospital Name:

In case of emergency, or if you find this card,  
please contact the doctor listed below:

## Dear HEALTHCARE PROFESSIONAL,

Daratumumab is associated with the risk of interference with blood typing. The Indirect Coombs test (Indirect antiglobulin test [IAT]) may show positive results in patients taking daratumumab, even in the absence of antibodies to minor blood antigens in the patient's serum which may persist for up to 6 months after the last dose. The determination of a patient's ABO and Rh blood type are not impacted.

If an emergency transfusion is required, non-cross-matched, ABO/RHD compatible RBCs can be given per local blood bank practices.

For more information, please contact local medical information service at Janssen: [infojaces@its.jnj.com](mailto:infojaces@its.jnj.com) or use this reference as a source of additional information: <http://onlinelibrary.wiley.com/doi/10.1111/trf.13069/epdf>

**Daratumumab PATIENTS: Show this card to healthcare professionals BEFORE blood transfusion and carry it with you for 6 months after treatment has ended**

**For further information please refer to the Patient Information Leaflet Patient ID Card for DARATUMUMAB**

Name \_\_\_\_\_

**I am taking the following medication:**

Daratumumab, antibody product for the treatment of multiple myeloma

I stopped taking this medication on: \_\_\_ / \_\_\_ / \_\_\_  
DD MM YYYY

**Before starting daratumumab my blood test results collected on**

\_\_\_ / \_\_\_ / \_\_\_ **were:**  
DD MM YYYY

Blood type:     A    B    AB    O    Rh+    Rh-

**Indirect Coombs test (antibody screening) was:**

Negative

Positive for the following antibodies:

Other: \_\_\_\_\_

Contact details of institution where the blood tests were performed:

\_\_\_\_\_  
\_\_\_\_\_

**Notification of adverse events:** If you experience any type of adverse event, contact your doctor or pharmacist, even if you are dealing with possible adverse events that do not appear in the package leaflet. You can also notify them directly through the Spanish Pharmacovigilance System of medicines for human use: <https://www.notificaRAM.es>